Environmental or self-antigens and homotypic interactions induce BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other signals in the microenvironment and growing the activation of anti-apoptotic and proliferation pathways. Duvelisib was the second PI3K inhibitor accepted with the FDA, also based upon a section III https://tommyo665cti3.blognody.com/profile